IFNG and neoplasm: The effector T cells secrete more IFN-γ, which binds to IFN-γ receptors on nearby tumor and normal cells, resulting in further increased MHC-I antigen presentation in those cells and enhancing additional TCR engagement and cytotoxic activity to malignant cells.